These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
184 related items for PubMed ID: 18990761
21. Genetics and epidemiology of ataxia-telangiectasia. Swift M. Kroc Found Ser; 1985; 19():133-46. PubMed ID: 3864935 [Abstract] [Full Text] [Related]
22. Genetic variation in IGF-1 and breast cancer risk in Ashkenazi carriers and noncarriers of BRCA1/2 mutations. Khoury-Shakour S, Lejbkowicz F, Barnett-Griness O, Tamir A, Pinchev M, Rennert G. Eur J Cancer Prev; 2009 Sep; 18(5):361-7. PubMed ID: 19543094 [Abstract] [Full Text] [Related]
23. Mortality rates among carriers of ataxia-telangiectasia mutant alleles. Su Y, Swift M. Ann Intern Med; 2000 Nov 21; 133(10):770-8. PubMed ID: 11085839 [Abstract] [Full Text] [Related]
28. Prevalence of breast and colorectal cancer in Ashkenazi Jewish carriers of Fanconi anemia and Bloom syndrome. Baris HN, Kedar I, Halpern GJ, Shohat T, Magal N, Ludman MD, Shohat M. Isr Med Assoc J; 2007 Dec 21; 9(12):847-50. PubMed ID: 18210922 [Abstract] [Full Text] [Related]
32. Mutations of the MYH gene do not substantially contribute to the risk of breast cancer. Beiner ME, Zhang WW, Zhang S, Gallinger S, Sun P, Narod SA. Breast Cancer Res Treat; 2009 Apr 21; 114(3):575-8. PubMed ID: 18454351 [Abstract] [Full Text] [Related]
33. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent. Evans DG, Lalloo F, Ashcroft L, Shenton A, Clancy T, Baildam AD, Brain A, Hopwood P, Howell A. Cancer Epidemiol Biomarkers Prev; 2009 Aug 21; 18(8):2318-24. PubMed ID: 19661091 [Abstract] [Full Text] [Related]
34. Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. Barrow E, Alduaij W, Robinson L, Shenton A, Clancy T, Lalloo F, Hill J, Evans DG. Clin Genet; 2008 Sep 21; 74(3):233-42. PubMed ID: 18554281 [Abstract] [Full Text] [Related]
35. Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline. van Os NJ, Roeleveld N, Weemaes CM, Jongmans MC, Janssens GO, Taylor AM, Hoogerbrugge N, Willemsen MA. Clin Genet; 2016 Aug 21; 90(2):105-17. PubMed ID: 26662178 [Abstract] [Full Text] [Related]
37. A preliminary report: frequency of A-T heterozygotes among prostate cancer patients with severe late responses to radiation therapy. Hall EJ, Schiff PB, Hanks GE, Brenner DJ, Russo J, Chen J, Sawant SG, Pandita TK. Cancer J Sci Am; 1998 Aug 21; 4(6):385-9. PubMed ID: 9853138 [Abstract] [Full Text] [Related]
38. Alport syndrome. Molecular genetic aspects. Hertz JM. Dan Med Bull; 2009 Aug 21; 56(3):105-52. PubMed ID: 19728970 [Abstract] [Full Text] [Related]
39. Age-specific incidence of breast cancer in breast cancer survivors and their first-degree relatives. Bertelsen L, Mellemkjaer L, Christensen J, Rawal R, Olsen JH. Epidemiology; 2009 Mar 21; 20(2):175-80. PubMed ID: 19057388 [Abstract] [Full Text] [Related]
40. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Hearle N, Schumacher V, Menko FH, Olschwang S, Boardman LA, Gille JJ, Keller JJ, Westerman AM, Scott RJ, Lim W, Trimbath JD, Giardiello FM, Gruber SB, Offerhaus GJ, de Rooij FW, Wilson JH, Hansmann A, Möslein G, Royer-Pokora B, Vogel T, Phillips RK, Spigelman AD, Houlston RS. Clin Cancer Res; 2006 May 15; 12(10):3209-15. PubMed ID: 16707622 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]